{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:02:25Z","timestamp":1780056145555,"version":"3.54.0"},"reference-count":10,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            antibacterial activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against 770 clinical isolates were investigated. Nemonoxacin (tested as its malate salt, TG-875649) showed better\n            <jats:italic>in vitro<\/jats:italic>\n            activity than ciprofloxacin and levofloxacin against different species of staphylococci, streptococci, and enterococci,\n            <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n            , and\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            . The\n            <jats:italic>in vitro<\/jats:italic>\n            activity of TG-875649 was also comparable to or better than that of moxifloxacin against these pathogens, which included ciprofloxacin-resistant, methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            and levofloxacin-resistant\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.01197-09","type":"journal-article","created":{"date-parts":[[2010,1,12]],"date-time":"2010-01-12T02:59:16Z","timestamp":1263265156000},"page":"1338-1342","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Comparative\n            <i>In Vitro<\/i>\n            Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones against Clinical Isolates"],"prefix":"10.1128","volume":"54","author":[{"given":"Tsai-Ling","family":"Lauderdale","sequence":"first","affiliation":[{"name":"National Health Research Institutes, Zhunan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ru","family":"Shiau","sequence":"additional","affiliation":[{"name":"National Health Research Institutes, Zhunan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Fen","family":"Lai","sequence":"additional","affiliation":[{"name":"National Health Research Institutes, Zhunan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Chien","family":"Chen","sequence":"additional","affiliation":[{"name":"TaiGen Biotechnology Co., Ltd., Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsin R.","family":"King","sequence":"additional","affiliation":[{"name":"TaiGen Biotechnology Co., Ltd., Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A7 2006"},{"key":"e_1_3_2_3_2","unstructured":"Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. 2008"},{"key":"e_1_3_2_4_2","unstructured":"Penicillin-nonsusceptibility and fluoroquinolone resistance in Streptococcus pneumoniae in Taiwan 2002-2008 2009"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.10.005"},{"key":"e_1_3_2_6_2","unstructured":"In vitro antibacterial activity of nemonoxacin (TG-873870) a new non-fluorinated quinolone against clinical isolates 2007"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1145"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2006.07.008"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00852-08"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.09.021"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1861-1864.2006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01197-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01197-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:23:16Z","timestamp":1645474996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01197-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1128\/AAC.01197-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.01197-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"2009-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-01-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}